Agilent Technologies, Inc. $A Shares Newly Acquired by Fulcrum Asset Management LLP

Key Points

• Fulcrum Asset Management initiated a position in Agilent Technologies, buying 27,889 shares worth approximately $4.9 million in the third quarter.
• Agilent beat quarterly earnings and revenue expectations, reporting EPS of $1.62 and revenue of $1.88 billion; revenue increased 8.1% year over year.
• Analysts rate the stock a “Moderate Buy,” with an average price target of $181.45. Recent target increases included Barclays’ move to $195.

Fulcrum Asset Management LLP purchased a new stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 27,889 shares of the medical research company's stock, valued at approximately $4,881,000.

A number of other hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in Agilent Technologies by 87.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company's stock worth $695,227,000 after buying an additional 2,440,360 shares during the period. Legal & General Group Plc purchased a new position in Agilent Technologies during the 2nd quarter worth approximately $260,101,000. Bank of America Corp DE acquired a new stake in Agilent Technologies during the 2nd quarter valued at approximately $213,269,000. Man Group plc acquired a new stake in Agilent Technologies during the 2nd quarter valued at approximately $179,257,000. Finally, Primecap Management Co. CA purchased a new stake in shares of Agilent Technologies in the 2nd quarter valued at $176,318,000.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $180.09 on Tuesday. The company's fifty day moving average price is $166.45 and its 200 day moving average price is $137.40. Agilent Technologies, Inc. has a 1 year low of $108.35 and a 1 year high of $182.99. The company has a market capitalization of $50.77 billion, a PE ratio of 35.45, a price-to-earnings-growth ratio of 2.59 and a beta of 1.24. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.49 by $0.13. The company had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The firm's revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the business earned $1.37 earnings per share. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts predict that Agilent Technologies, Inc. will post 6.20 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 28th. Investors of record on Tuesday, October 6th were paid a $0.2550 dividend. This represents a $1.02 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Tuesday, October 6th. Agilent Technologies's payout ratio is currently 20.08%.

Insider Buying and Selling at Agilent Technologies

In related news, Director Mikael Dolsten sold 634 shares of the company's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $151.38, for a total value of $95,974.92. Following the completion of the transaction, the director owned 4,924 shares of the company's stock, valued at approximately $745,395.12. This represents a 11.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on A. UBS Group increased their price objective on shares of Agilent Technologies from $165.00 to $180.00 in a research note on Tuesday, October 13th. The Goldman Sachs Group boosted their target price on shares of Agilent Technologies from $175.00 to $185.00 and gave the company a "buy" rating in a research report on Monday, September 21st. Barclays upped their price target on shares of Agilent Technologies from $175.00 to $195.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Weiss Ratings raised Agilent Technologies from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, October 8th. Finally, Rothschild & Co Redburn lifted their price objective on Agilent Technologies from $160.00 to $180.00 and gave the company a "buy" rating in a research note on Thursday, August 27th. Eighteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $181.45.

Agilent Technologies Company Profile

Agilent Technologies develops and supplies instruments, software, services and consumables used in laboratories and manufacturing operations. Its offerings support applications in life sciences, diagnostics, chemical analysis, food safety, environmental testing and pharmaceutical research.

The company serves customers worldwide, including pharmaceutical and biotechnology companies, clinical and academic laboratories, and organizations in the chemical, energy and food industries. Its services include laboratory equipment maintenance, technical support and related workflow solutions.

Agilent became an independent company in 1999 through a spin-off from Hewlett-Packard.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.